India IPS Cell-Derived Organoids Market Research Report By Type (Brain Organoids, Heart Organoids, Lung Organoids, Liver Organoids, Kidney Organoids, Others), By Application (Drug Discovery and Development, Disease Modelling, Regenerative Medicine) and By End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Contract Research Organization) - Forecast to 2035

India iPS Cell-Derived Organoids Market Overview

As per MRFR analysis, the India iPS Cell-Derived Organoids Market Size was estimated at 17.6 (USD Million) in 2023. The India iPS Cell-Derived Organoids Market Industry is expected to grow from 20.4(USD Million) in 2024 to 82 (USD Million) by 2035. The India iPS Cell-Derived Organoids Market CAGR (growth rate) is expected to be around 13.482% during the forecast period (2025 - 2035)

Key India iPS Cell-Derived Organoids Market Trends Highlighted

The India iPS Cell-Derived Organoids Market is witnessing significant trends driven by advancements in regenerative medicine and biotechnology. The government of India is increasingly investing in research and development, particularly in areas like stem cell technology and personalized medicine. Initiatives such as the National Biotechnology Development Strategy aim to promote the growth of innovative therapies, including those utilizing iPS cells. The support from regulatory bodies, alongside growing research facilities, creates a conducive environment for the development of organoids derived from iPS cells, which offer immense potential in drug discovery and disease modeling. 

Opportunities in India’s market are expanding as pharmaceutical and biotechnology companies begin to recognize the application of iPS cell-derived organoids in accelerating drug development processes. Collaborations between academia and industry are on the rise, providing a platform for innovation and improved treatment methodologies. Furthermore, India’s large patient population presents an opportunity for clinical trials and studies, which can significantly contribute to the research landscape and lead to the commercialization of breakthroughs in cellular therapies. In recent times, there has been a noticeable trend of increased awareness and acceptance of advanced cell therapies in India.

The educational institutions and research institutes are increasingly incorporating iPS cell technology into their curricula, fostering a new generation of scientists. Public-private partnerships are also enhancing the accessibility of advanced research tools and technology. The emergence of startups focused on iPS cell-derived organoids highlights a shift towards a vibrant ecosystem that encourages innovation. This dynamic landscape encourages continuous exploration of potential applications of organoids in understanding complex diseases and developing targeted therapies tailored to the Indian demographic.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

India iPS Cell-Derived Organoids Market Drivers

Increasing Investment in Stem Cell Research

Investments in stem cell research are increasing, which is driving the India iPS Cell-Derived Organoids Market Industry. As seen by the Indian Council of Medical Research's efforts to foster creative healthcare solutions, the Indian government has been aggressive in advancing research and development in this area. Over the past five years, the government has granted more than $100 million USD to a number of R&D initiatives that are especially concerned with stem cells and regenerative medicine. 

Advances in organoids and iPS cell therapies—both essential for personalized treatment and disease modeling—are being made possible by this emphasis on innovation. Companies like the National Institute of Stem Cell Research and the Department of Biotechnology (DBT) are essential in enabling these developments, which are driving the market's expansion.

Rising Prevalence of Chronic Diseases

The prevalence of chronic diseases such as cancer, diabetes, and neurological disorders in India is a significant driver for the India iPS Cell-Derived Organoids Market Industry. According to a report released by the Government of India, the number of diabetes patients has surged to 77 million in 2021, and cancer cases are projected to reach 2.25 million by 2025. 

This alarming rise in chronic health issues is prompting healthcare professionals and researchers to seek advanced therapies, including the use of iPS cell-derived organoids for drug discovery and personalized treatment methodologies.Established organizations, including Tata Memorial Hospital and Apollo Hospitals, are actively involved in integrating organoid technologies into their treatment protocols, catering to the growing need for innovative healthcare solutions.

Advancements in Biotechnology and Bioengineering

Advancements in biotechnology and bioengineering are propelling the India iPS Cell-Derived Organoids Market Industry forward. The Indian government has recognized the importance of these technological innovations and is pushing for Policies that support the biotechnology sector. The Biotechnology Industry Research Assistance Council (BIRAC) has provided various grants totaling approximately 50 million USD to startups specializing in biotechnology solutions that encompass organoid research.

This momentum in biotechnology is facilitating progress in developing organoids for disease modeling and regenerative medicine, offering significant opportunities for research institutions and startups alike. Notable players in this space, such as Biocon and Cadila Healthcare, are investing in integrating organoid technologies for better therapeutic applications.

India iPS Cell-Derived Organoids Market Segment Insights

iPS Cell-Derived Organoids Market Type Insights

The India iPS Cell-Derived Organoids Market exhibits a diverse Type segmentation that reflects the unique applications and research advancements across various organoids. Among these, Brain Organoids are significant as they offer insights into neurodevelopment and neurodegenerative diseases, making them a focal point for Research and Development in neurological studies. Meanwhile, Heart Organoids play a crucial role in cardiovascular research, helping scientists understand heart diseases and test drug responses, which can lead to more effective therapies.Lung Organoids, on the other hand, have gained importance in the context of respiratory diseases, including infections and chronic conditions, thus serving as a model for developing targeted treatments. 

Liver Organoids are valuable in drug metabolism studies and understanding liver diseases, providing a pathway for personalized medicine approaches. Kidney Organoids support research into renal diseases, which are prevalent in India, by facilitating studies on nephrotoxicity and kidney function. Additionally, the Others category encompasses diverse organoid types that cater to niche segments in research, reflecting the broad utility of iPS cell-derived technologies.The growing emphasis on regenerative medicine and personalized therapy is driving innovation in these segments, as various stakeholders, including academic institutions and biotech firms, aim to leverage organoid models for drug testing, disease modeling, and therapeutic innovations. 

This variety within the iPS Cell-Derived Organoids Market illustrates the potential for significant advancements in understanding complex organ systems and addressing critical health challenges in India. Factors such as increasing research funding, technological advancements, and a rising prevalence of chronic diseases are expected to further bolster the growth of these organoid segments, thus shaping the future landscape of healthcare research in the region.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

iPS Cell-Derived Organoids Market Application Insights

The Application segment of the India iPS Cell-Derived Organoids Market plays a pivotal role in advancing biomedical research and therapeutics. Drug Discovery and Development is significant as it allows researchers to expedite the testing of new compounds using human-like organoid models, which significantly reduce the need for animal testing and increase the relevance of findings to human patients. Disease Modelling serves a crucial function by enabling scientists to create accurate representations of various diseases, making it easier to study disease progression and evaluate potential treatment options.

Regenerative Medicine holds promise for addressing several chronic conditions through cellular therapies, where iPS cell-derived organoids can potentially lead to breakthroughs in restoring function and improving patient outcomes. The escalating prevalence of chronic diseases in India further fuels the demand within these applications, supporting the advancement of precision medicine and personalized treatment strategies. Overall, the growing investments in biotechnology and healthcare infrastructure are likely to enhance the capabilities and functionalities of iPS Cell-Derived Organoids in these vital applications, contributing to the larger landscape of the India iPS Cell-Derived Organoids Market.

iPS Cell-Derived Organoids Market End User Insights

The End User segment of the India iPS Cell-Derived Organoids Market plays a crucial role in driving innovation and addressing various medical challenges. Pharmaceutical and Biotechnology Companies are significant players, leveraging these organoids for drug discovery and toxicity testing, leading to enhanced drug development processes. Academic and Research Institutes contribute to this market by conducting extensive Research and Development on disease modeling and regenerative medicine, thus fostering collaboration with industry counterparts for clinical advancements.

Contract Research Organizations are vital for providing outsourced services to pharmaceutical companies, facilitating efficient research pipelines and helping to streamline regulatory processes. Their growing involvement reflects the importance of utilizing iPS cell-derived organoids in preclinical studies, illustrating the demand for sophisticated models that predict human response more accurately. As the India iPS Cell-Derived Organoids Market evolves, the interconnectivity and synergy between these end users are essential for advancing personalized medicine and improving therapeutic outcomes across various diseases.

India iPS Cell-Derived Organoids Market Key Players and Competitive Insights

The India iPS Cell-Derived Organoids Market is an emerging sector that exhibits significant potential due to the advancements in regenerative medicine and stem cell technology. This market is characterized by an increasing demand for innovative cell-based therapies and drug discovery models that allow researchers to replicate human organ functions in vitro, thereby reducing the reliance on animal testing. The competitive landscape is driven by various players who are investing in research and development to formulate advanced organoid technologies. Given the growing interest from pharmaceutical and biotechnology companies, regulatory support, and an expanding academic base, the market is witnessing a surge in collaborations and partnerships among key industry stakeholders. 

Stemcell Technologies has established a strong foothold within the India iPS Cell-Derived Organoids Market through its robust portfolio of products catering to stem cell research. The company focuses on providing high-quality cell culture tools and reagents that facilitate the growth and differentiation of iPS cells into organoids. Its strengths lie in its commitment to innovation, an extensive array of specialized products, and a well-established reputation for reliability among researchers and institutions in India. The company actively participates in collaborations with local academic institutions to advance the field of stem cell research and organoid technology, further enhancing its presence in the market.

Organogenesis is a notable player in the India iPS Cell-Derived Organoids Market, known for its specialized products and comprehensive services tailored for regenerative medicine applications. The company focuses on developing organoid technologies that have applications in drug discovery and personalized medicine. With a strong market presence, Organogenesis emphasizes the scalability of its organoid models to meet diverse research needs. The company has made noteworthy strides in leveraging partnerships and strategic alliances to expand its product offerings within India. 

Its strengths include the ability to provide customized solutions, a commitment to quality, and a strong emphasis on research and development, which positions it effectively in the competitive landscape. By continuously innovating and potentially engaging in mergers and acquisitions, Organogenesis aims to further strengthen its market presence and expand its portfolio in the region.

Key Companies in the India iPS Cell-Derived Organoids Market Include

• Stemcell Technologies


• Organogenesis


• Evercyte


• Organovo


• Sangamo Therapeutics


• R&D Systems


• Cellectis


• Takara Bio


• Thermo Fisher Scientific


• MilliporeSigma


• Corning


• Astellas Pharma


• Axiogenesis


• Reprogramming Technologies


• Cellular Dynamics International

India iPS Cell-Derived Organoids Market Industry Developments

Recent developments in the India iPS Cell-Derived Organoids Market indicate a significant growth trajectory, influenced by advancements in cellular technology and increasing applications in drug discovery and regenerative medicine. Companies such as Stemcell Technologies, Takara Bio, and Organogenesis are expanding their operations in India, focusing on the development of specialized organoids for personalized medicine. In September 2023, Takara Bio announced a partnership with Cellular Dynamics International to enhance its capabilities in organoid production. There are no reported mergers or acquisitions among the listed companies in the past few months. 

Over the last two to three years, the market has seen substantial investment, with the Indian government incentivizing biotechnological research and innovation, facilitating a conducive environment for organizations like MilliporeSigma and Corning to establish research and development facilities. Furthermore, a recent valuation in March 2023 estimated that the Indian iPS Cell-Derived Organoids Market could reach new heights, driven by increasing collaborations among biotech firms and research institutions aiming to leverage stem cell technologies for clinical applications. These developments reveal India's growing prominence in regenerative medicine and organoid research on a global scale.

India iPS Cell-Derived Organoids Market Segmentation Insights

iPS Cell-Derived Organoids Market Type Outlook

• Brain Organoids


• Heart Organoids


• Lung Organoids


• Liver Organoids


• Kidney Organoids


• Others

iPS Cell-Derived Organoids Market Application Outlook

• Drug Discovery and Development


• Disease Modelling


• Regenerative Medicine

iPS Cell-Derived Organoids Market End User Outlook

• Pharmaceutical and Biotechnology Companies


• Academic and Research Institutes


• Contract Research Organization

Report Attribute/Metric Source:	Details
MARKET SIZE 2023	17.6(USD Million)
MARKET SIZE 2024	20.4(USD Million)
MARKET SIZE 2035	82.0(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)	13.482% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Million
KEY COMPANIES PROFILED	Stemcell Technologies, Organogenesis, Evercyte, Organovo, Sangamo Therapeutics, R&D Systems, Cellectis, Takara Bio, Thermo Fisher Scientific, MilliporeSigma, Corning, Astellas Pharma, Axiogenesis, Reprogramming Technologies, Cellular Dynamics International
SEGMENTS COVERED	Type, Application, End User
KEY MARKET OPPORTUNITIES	Research funding growth, Technological advancements in organoid culture, Drug discovery and testing applications, Personalized medicine development, Regenerative medicine innovations
KEY MARKET DYNAMICS	technological advancements, increasing research funding, rising prevalence of diseases, government support for stem cell research, growing demand for personalized medicine
COUNTRIES COVERED	India